These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32064608)

  • 1. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
    Englinger B; Laemmerer A; Moser P; Kallus S; Röhrl C; Pirker C; Baier D; Mohr T; Niederstaetter L; Meier-Menches SM; Gerner C; Gabler L; Gojo J; Timelthaler G; Senkiv J; Jäger W; Kowol CR; Heffeter P; Berger W
    Int J Cancer; 2020 Sep; 147(6):1680-1693. PubMed ID: 32064608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.
    Englinger B; Kallus S; Senkiv J; Heilos D; Gabler L; van Schoonhoven S; Terenzi A; Moser P; Pirker C; Timelthaler G; Jäger W; Kowol CR; Heffeter P; Grusch M; Berger W
    J Exp Clin Cancer Res; 2017 Sep; 36(1):122. PubMed ID: 28882160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
    Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
    Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
    Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
    Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
    Ng TL; Yu H; Smith DE; Boyle TA; York ER; Leedy S; Gao D; Aisner DL; Van Bokhoven A; Heasley LE; Hirsch FR; Camidge DR
    Clin Lung Cancer; 2019 Jan; 20(1):e39-e51. PubMed ID: 30297175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
    Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
    Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
    Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
    Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
    Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index.
    Kallus S; Englinger B; Senkiv J; Laemmerer A; Heffeter P; Berger W; Kowol CR; Keppler BK
    Nanomedicine; 2018 Nov; 14(8):2632-2643. PubMed ID: 30121385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
    Ren M; Qin H; Ren R; Cowell JK
    Leukemia; 2013 Jan; 27(1):32-40. PubMed ID: 22781593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
    Lang JD; Hendricks WPD; Orlando KA; Yin H; Kiefer J; Ramos P; Sharma R; Pirrotte P; Raupach EA; Sereduk C; Tang N; Liang WS; Washington M; Facista SJ; Zismann VL; Cousins EM; Major MB; Wang Y; Karnezis AN; Sekulic A; Hass R; Vanderhyden BC; Nair P; Weissman BE; Huntsman DG; Trent JM
    Clin Cancer Res; 2018 Apr; 24(8):1932-1943. PubMed ID: 29440177
    [No Abstract]   [Full Text] [Related]  

  • 14. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
    Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.
    Kanojia D; Garg M; Martinez J; M T A; Luty SB; Doan NB; Said JW; Forscher C; Tyner JW; Koeffler HP
    J Hematol Oncol; 2017 Nov; 10(1):173. PubMed ID: 29132397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
    Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
    Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.
    Laramy JK; Kim M; Parrish KE; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2018 May; 365(2):249-261. PubMed ID: 29440450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
    Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
    Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.